Form 4: Vanda Pharmaceuticals Director Awarded Significant Restricted Stock Units

Phaedra Chrousos, a Director at Vanda Pharmaceuticals Inc., was granted 59,225 restricted stock units, increasing her total beneficial ownership to 123,350 shares.

Summary

• Phaedra Chrousos, a Director of Vanda Pharmaceuticals Inc. (VNDA), acquired 59,225 shares of common stock on June 5, 2025.
• These shares represent a time-based restricted stock unit (RSU) award, with an acquisition price of $0 per share, which is typical for equity grants.
• The RSU award is scheduled to vest 100% on June 5, 2026, contingent upon Ms. Chrousos providing continuous service to the Issuer through the vesting date.
• Following this transaction, Ms. Chrousos's total beneficial ownership of Vanda Pharmaceuticals common stock increased to 123,350 shares.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive sign of alignment and retention, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of 59,225 restricted stock units to a director aligns management and director interests with long-term shareholder value.
• The vesting schedule, contingent on continuous service until June 5, 2026, promotes the retention of key personnel within the company.

Risks

• The vesting of the restricted stock units is contingent on continuous service; therefore, the shares could be forfeited if the director's service ceases before June 5, 2026.

Future Outlook

The grant of restricted stock units with a future vesting date indicates an expectation of continued service from the director and aligns their incentives with the company's long-term performance through June 2026.

Industry Context

Equity compensation, particularly through restricted stock units (RSUs), is a common practice across the pharmaceutical and biotechnology industries to attract, retain, and incentivize key talent, including directors, by aligning their interests with long-term shareholder value. This practice is standard for publicly traded companies.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation is a standard practice in the pharmaceutical and broader corporate sectors, aligning director incentives with long-term company performance.
• The vesting schedule, contingent on continuous service, is typical for RSU awards across industries, including companies like Pfizer, Johnson & Johnson, and Merck, which also utilize similar equity compensation structures for their executives and directors.
• The grant size of 59,225 shares for a director at a company like Vanda Pharmaceuticals (market capitalization typically in the hundreds of millions) is within a reasonable range for non-executive director equity compensation, though specific comparisons would require detailed compensation peer group analysis.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with long-term shareholder value, as the value of the award is tied to the company's stock performance.
• Employees: While not directly impacting all employees, this type of equity compensation for directors sets a precedent for how the company values and incentivizes its leadership.

Next Steps

• Phaedra Chrousos is expected to continue her service as a Director of Vanda Pharmaceuticals Inc. until at least June 5, 2026, for the RSU award to fully vest.

Key Dates

Recommendation

Keywords

Vanda Pharmaceuticals, VNDA, Form 4, SEC filing, insider transaction, restricted stock unit, RSU, director compensation, equity award, beneficial ownership